Categories
Gland Pharma Limited — Important, 15-05-2026: Updates
15-05-2026 · 04:59 pm
Gland Pharma reports strong Q4 FY26: Revenue up 22% YoY to ₹1,742.8 Cr, Adj. PAT surged 97% to ₹366.7 Cr. FY26 revenues grew 14.5% to ₹6,430.7 Cr, PAT by 50% to ₹1,045.5 Cr. Board announced ₹20/share final dividend. Growth driven by CDMO expansion and new US launches.
No comments yet. Be the first to comment!